Profile signs obstructive sleep apnoea agreement
Profile Therapeutics, which develops and commercialises specialist inhaled therapies, has signed an agreement with Grampian University Hospitals NHS Trust for the supply of its sleep therapy services.
Profile Therapeutics, which develops and commercialises specialist inhaled therapies, has signed an agreement with Grampian University Hospitals NHS Trust for the supply of its sleep therapy services.
Under the terms of the five-year agreement Profile will supply Grampian with equipment, consumables and its innovative internet-based patient compliance service 'Management of Sleep Therapy' (MOST). The comprehensive MOST service is aimed at relieving some of the increasing burden of patient management allowing clinicians more time to diagnose and treat more patients.
The agreement covers an initial 287 patients and Profile will receive an annual fee for each patient. Profile believes that Grampian is the first NHS trust to transfer management of this patient group to a third party.
Obstructive Sleep Apnoea (OSA) is caused by the restriction of the upper airways during sleep prevent-ing adequate breathing and resulting in highly disturbed and broken sleep. As it occurs in approximately 4% of the adult male population it represents an important additional opportunity for Profile.
Commenting on the announcement, John Lisle, chief executive of Profile, said: 'I am delighted that we are working with Grampian on the provision of cutting-edge patient support and compliance management systems. Early indications from the first patients transferred to MOST are that the systems are working very well and patient compliance is already improving. We intend to extend the use of MOST to important at-risk groups.'